Nolt Valerie D, Patel Tulsi M, Forbes-Osborne Marie A, Osborne Samuel B, Gardner Brian M, Kuhn Robert J
J Pediatr Pharmacol Ther. 2020;25(2):139-148. doi: 10.5863/1551-6776-25.2.139.
Compared with adults, children may be at greater risk of medication errors and potential adverse effects. The American Academy of Pediatrics recommends developing mechanisms for proactively identifying patients at risk for medication-related adverse events and failed reconciliation. This study's primary purpose was to evaluate pediatric patients admitted to identify risk factors requiring pharmacist intervention during medication reconciliation (MedRec).
This prospective study included pediatric patients admitted during the study time frame until the target population of 500 patient encounters was achieved. During each admission, pharmacy staff completed a medication history, after which a pediatric pharmacist completed a MedRec, as is standard hospital practice. The primary outcome was identification of factors for high-risk transitions of care during pediatric admissions based on the need for pharmacist interventions during the MedRec process.
In total, 331 interventions were made for 127 patients (median 2; range, 1-12). Of the 331 interventions, 196 (59.2%) were classified as being of moderate or significant severity. Although patients with at least 2 home medications were significantly more likely to require any intervention (p < 0.0001), patients with 5 or more home medications were more likely to have a significant intervention.
Identifying patients with home medications could allow for focused efforts to intervene. Also, patients admitted to the PICU or those with cardiology- or endocrinology-related diagnoses should be prioritized for MedRec process, because of the likelihood of requiring multiple home medications. This strategy should be tailored to individual pediatric institutions based on internal quality control assessments and available resources.
与成人相比,儿童用药错误和潜在不良反应的风险可能更高。美国儿科学会建议建立机制,以主动识别有用药相关不良事件风险和用药核对失败的患者。本研究的主要目的是评估住院儿科患者,以确定在用药核对(MedRec)期间需要药剂师干预的风险因素。
这项前瞻性研究纳入了在研究时间段内入院的儿科患者,直至达到500例患者诊疗的目标人群。在每次入院期间,药房工作人员完成用药史记录,之后按照医院标准流程,由一名儿科药剂师完成用药核对。主要结局是根据用药核对过程中对药剂师干预的需求,确定儿科住院期间高风险护理转接的因素。
总共对127例患者进行了331次干预(中位数为2次;范围为1 - 12次)。在这331次干预中,196次(59.2%)被归类为中度或重度。虽然至少有2种家庭用药的患者更有可能需要任何干预(p < 0.0001),但有5种或更多家庭用药的患者更有可能需要进行重大干预。
识别有家庭用药的患者有助于集中精力进行干预。此外,入住儿科重症监护病房(PICU)的患者或患有心脏病或内分泌疾病相关诊断的患者,应在用药核对过程中优先考虑,因为他们可能需要多种家庭用药。应根据内部质量控制评估和可用资源,为各个儿科机构量身定制这一策略。